The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.75
Bid: 41.00
Ask: 42.50
Change: 5.25 (14.38%)
Spread: 1.50 (3.659%)
Open: 37.00
High: 42.50
Low: 36.00
Prev. Close: 36.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

Tue, 02nd Jan 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

LungLife AI Inc, up 36% at 62.33 pence, 12-month range 19.00p-141.10p. The developer of clinical diagnostic solutions designed to address the early detection of lung cancer announces the successful validation of its LungLB test for indeterminate lung nodules. This is from a "prospective, multi-site clinical study in the clinically important small nodules patient group". The LungLB test is a blood-based tool used by clinicians to help with earlier diagnosis of lung cancer nodules. The diagnostic demonstrates a positive predictive value of 81% in distinguishing benign from cancerous lung nodules in patients with nodules smaller than 15 millimetres. This surpasses the current clinical standard of around 60%. According to LungLife, the results are sufficient for publication and the execution of its commercial programme for LungLB. The initial launch will be through an early access program offered from its California laboratory in the first quarter of 2024.

----------

Sareum Holdings PLC, up 19% at 71.00p, 12-month range 50.00p-149.00p. The pharmaceutical company's co-development partner CRT Pioneer Fund enters into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company. SRA737 is a clinical-stage oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Sareum says an immediate upfront payment of USD500,000 is due to CRT Pioneer Fund, while an additional fee made up of up to USD1.0 million cash and 500,000 shares in the licensee company may be payable upon the sooner 12 months following the signing of the licencing agreement, or if the licensee company achieves certain commercial and material financing objectives. A further announcement regarding any future income, including any shares which may be issued, will be made "at the appropriate time".

----------

AIM - LOSERS

----------

Plexus Holdings PLC, down 15% at 17.94p, 12-month range 1.60p-31.40p. The oil and gas engineering services business completes an agreement with SLB to replace an existing surface production wellhead licence with a new licence over a wider field of use for USD5.2 million in cash. It says SLB acquires a perpetual royalty free license for Pos-Grip technology and HG seal technology plus any improvements, enhancements, or derivatives to the technology for surface wellhead production applications for all pressure and size ranges. Plexus says the licence scope includes oil and gas production and storage applications, as well as carbon dioxide storage and hydrogen storage, alongside water and cuttings reinjection. Plexus Chief Executive Officer Ben van Bilderbeek says: "This new licence agreement is a further validation of Plexus' [intellectual property] by this leading energy technology company and recognises the contribution our leak-proof POS-GRIP wellhead equipment can make to the oil and gas industry's [environmental, social and governance] and net zero goals."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Apr 2021 12:17

Sareum shares rise after improved interim results, research progress

Sareum shares rise after improved interim results, research progress

Read more
16 Feb 2021 13:56

IN BRIEF: Sareum Notes Launch Of UK Government's Agile Platform

IN BRIEF: Sareum Notes Launch Of UK Government's Agile Platform

Read more
7 Jan 2021 12:52

Sareum gets approval for US patent application

(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office has now formally approved its patent application, number 16/351,620.

Read more
7 Jan 2021 10:51

UK WINNERS & LOSERS SUMMARY: Mitchells & Butlers Down Amid Raise Plan

UK WINNERS & LOSERS SUMMARY: Mitchells & Butlers Down Amid Raise Plan

Read more
7 Jan 2021 09:53

Sareum Shares Rise On Granting Of Patent For SDC-1802 Inhibitor

Sareum Shares Rise On Granting Of Patent For SDC-1802 Inhibitor

Read more
16 Dec 2020 22:00

IN BRIEF: Sareum Makes Progress On Potential Covid Treatment Candidate

IN BRIEF: Sareum Makes Progress On Potential Covid Treatment Candidate

Read more
14 Dec 2020 12:27

Sareum Shares Surge 30% After Study Results Support Covid-19 Programme

Sareum Shares Surge 30% After Study Results Support Covid-19 Programme

Read more
8 Dec 2020 15:51

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
3 Dec 2020 15:45

IN BRIEF: Sareum Gets GBP174,000 To Research Potential Virus Treatment

IN BRIEF: Sareum Gets GBP174,000 To Research Potential Virus Treatment

Read more
3 Dec 2020 12:19

Sareum Holdings secures grant for Covid-19 treatment project

(Sharecast News) - Specialist drug development company Sareum Holdings announced on Thursday that the grant offer letter from UK Research and Innovation (UKRI) had now been received and approved.

Read more
12 Nov 2020 19:17

UK TRADING UPDATE SUMMARY: Clipper Expects 20% Interim Revenue Climb

UK TRADING UPDATE SUMMARY: Clipper Expects 20% Interim Revenue Climb

Read more
27 Oct 2020 15:16

IN BRIEF: Sareum Nets Covid-19 Therapy UK Research Grant

IN BRIEF: Sareum Nets Covid-19 Therapy UK Research Grant

Read more
13 Oct 2020 13:54

IN BRIEF: Sareum Loss Narrows On Reduced Administration Expenses

IN BRIEF: Sareum Loss Narrows On Reduced Administration Expenses

Read more
8 Oct 2020 19:54

UK TRADING UPDATE SUMMARY: Motorpoint Predicts Local Lockdowns Bite

UK TRADING UPDATE SUMMARY: Motorpoint Predicts Local Lockdowns Bite

Read more
8 Oct 2020 15:50

Sareum to get US patent on SDC-1802 programme

(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent on an invention associated with its proprietary 'SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.